Navigation Links
Cervical Cancer Vaccine Seems Safe
Date:8/18/2009

Fainting most common adverse event with Gardasil, study finds,,

TUESDAY, Aug. 18 (HealthDay News) -- The vaccine that protects against human papillomavirus (HPV), a cause of cervical cancer, appears safe, with relatively few serious side effects, according to a new U.S. government study.

The study, which included data from the voluntary Vaccine Adverse Event Reporting System (VAERS), found that the rate of serious adverse events for the vaccine, marketed under the brand name of Gardasil, was similar to data from earlier clinical trials, except for rates of fainting and blood clots.

For every 100,000 doses of HPV vaccine distributed, the study found 8.2 episodes of fainting and 0.2 episodes involving blood clotting. The study is published in the Aug. 19 issue of the Journal of the American Medical Association.

"Basically, we didn't see anything that surprising. This is a safe vaccine," said the study's lead author, Dr. Barbara Slade, a medical officer in the immunization safety office at the U.S. Centers for Disease Control and Prevention. "Syncope [fainting] is the most commonly seen adverse event."

As for the increased rate of serious incidents of blood clotting, Slade said that most of the girls or women who had such problems had other characteristics that increased their risk for clots.

"It's a complicated issue," she said. "Most of these girls had another risk factor for blood clots, but we don't want to dismiss the blood clots. We need to know if it's something that's truly unrelated, and we're recommending that this finding be looked at a little bit closer."

In June 2006, Gardasil was licensed for use in girls older than 9 years to prevent infection from four types of HPV. HPV is a virus known to cause genital warts and cervical cancer. Two types of HPV covered by the vaccine, HPV-16 and HPV-18, cause about 70 percent of cervical cancers worldwide. The vaccine is given in three doses.

In clinical trials conducted before licensing, researchers found that the rates of adverse events were similar in girls and young women who received the vaccine compared with those who received a placebo injection.

For the new study, researchers from the CDC and the U.S. Food and Drug Administration reviewed data from VAERS, the voluntary system that enables anyone to report a vaccine-related side effect. Slightly more than two-thirds of the information on Gardasil was provided to VAERS by the drug's manufacturer, Merck & Co.

The researchers reviewed data from the time Gardasil was approved in 2006 through December 2008. During that time, 23 million doses of Gardasil were distributed throughout the United States, Merck said.

More than 12,000 reports of adverse events after vaccination were reported to VAERS. Of those, 772 were described as serious, including 32 deaths, the study found.

Slade said that when the researchers reviewed the deaths, they couldn't discern any pattern. Those who died were of different ages, there wasn't a common cause of death, and there wasn't a consistent time after vaccination that these deaths occurred.

"While this is heart-rending for the family involved because you don't expect deaths in this age group, our general feeling is that they're not vaccine-related," she said.

Other reported adverse events included local reactions, such as redness, swelling or pain at the injection site, dizziness, nausea, headache, allergic reactions and autoimmune disorders.

"We're pleased with the JAMA paper as it confirms the safety profile of Gardasil," said Dr. Richard Haupt, executive director of clinical research at Merck Research Laboratories. "The benefit-to-risk profile is very favorable," he added.

Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, said it won't be making any changes to its recommendations, which suggest that young women receive the Gardasil vaccine to protect against some cervical cancers. But, he added, this study "is not the final or definitive answer."

Lichtenfeld pointed out, as did the study authors, that because VAERS is a voluntary system, it might underestimate the actual number of adverse events because some could go unreported. "More specific scientific studies need to be done," he said.

As for the episodes of fainting, Merck -- as well as the CDC -- recommends that anyone receiving the vaccine stay in the doctor's office for at least 15 minutes after receiving a shot.

The CDC's Slade also recommended that parents drive their teens to their appointments so the teens are not driving if a fainting episode should occur. And, because vaccines are often administered during physicals for which people have been asked to fast, Slade also suggested eating a quick snack and drinking something before getting the vaccine but after having blood drawn for the physical.

More information

The U.S. Centers for Disease Control and Prevention has more about the HPV vaccine.



SOURCES: Barbara Slade, M.D., M.S., medical officer, immunization safety office, U.S. Centers for Disease Control and Prevention, Atlanta; Richard Haupt, M.D., M.P.H., executive director, clinical research, infectious diseases and vaccines, Merck Research Laboratories, Whitehouse Station, N.J.; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Aug. 19, 2009, Journal of the American Medical Association


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cervical cancer screening: Too many are left unprotected
2. Couples more likely to divorce if spouse develops cervical or testicular cancer
3. Gene-Based Screen Spots Cervical Cancer Earlier
4. Transcutaneous cervical esophageal ultrasound can not substitute for 24-h pH monitoring or manometry
5. Advaxis, Inc. phase I/II results of lovaxin C in cervical cancer study released
6. Study: HPV test beats Pap in detecting cervical cancer
7. NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
8. Pa. Funding for Cervical Cancer Prevention Services Ends
9. Precancerous Lesions Raise Cervical Cancer Risk
10. American Medical Womens Association Supports New Bill That Requires Medicare Coverage of HPV Testing as Part of Cervical Cancer Screening
11. Study Finds New Version of QIAGENs HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: